To understand why front-line treatment with hypomethylating agents fail in many patients with MDS and AML, this moon shot team has developed cell lines resistant to these agents and conducted investigative studies. Genomic and proteomic analyses of these cell lines have resulted in significant new knowledge about therapy resistance. Our leukemia experts are partnering with drug companies and have started clinical trials for patients with resistant disease, including the first immune checkpoint blockade trial in leukemia, a type of cancer immunotherapy.
Overcoming a sad reality
MDS and AML are among the most tragic leukemias in terms of prognosis. There’s no cure for MDS, and AML has a cure rate of less than 30%. But MD Anderson physicians and scientists give patients hope.